These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 14672404)

  • 1. Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer.
    Hartman AR; Grekowicz A; Lum BL; Carlson RW; Schurman C; Sikic BI; Shapiro R; Stockdale FE
    Breast Cancer Res Treat; 2003 Nov; 82(1):61-9. PubMed ID: 14672404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer.
    Hortobagyi GN; Young RR; Karwal M; Ibrahim NK; Hermann R; Murray JL; Watkins SP; Gore I
    Cancer; 2010 May; 116(10):2301-6. PubMed ID: 20225231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.
    Hortobagyi GN; Heim W; Hutchins L; Rivera E; Mason B; Booser DJ; Kirshner J
    Cancer; 2010 Mar; 116(6):1440-5. PubMed ID: 20091835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
    Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
    Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
    Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies.
    Passardi A; Maltoni R; Milandri C; Cecconetto L; Massa I; Zoli W; Tesei A; Fabbri F; Nanni O; Amadori D
    Oncology; 2007; 72(1-2):118-24. PubMed ID: 18004083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
    Surmont V; Aerts JG; Pouw E; Tan KY; Vernhout R; Gras J; Salomé J; Pronk T; Schmitz PI; Hoogsteden H; van Klaveren RJ
    Lung Cancer; 2009 Dec; 66(3):333-7. PubMed ID: 19327865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
    Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
    J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer.
    Chen JS; Rau KM; Chen YY; Huang JS; Yang TS; Lin YC; Liau CT; Lee KD; Su YC; Kao RH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):819-25. PubMed ID: 18663448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
    Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
    Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
    Czito BG; Cohen DP; Kelsey CR; Lockhart AC; Bendell JC; Willett CG; Petros WP; D'Amico TA; Truax R; Hurwitz HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1066-72. PubMed ID: 17881149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.
    Idelevich E; Karminsky N; Dinerman M; Katsenelson RL; Zvi NB; Baruch NB; Biran H; Man S; Shani A
    Acta Oncol; 2007; 46(3):324-9. PubMed ID: 17450467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial.
    Villanueva C; Chaigneau L; Dufresne A; Thierry Vuillemin A; Stein U; Demarchi M; Bazan F; N'guyen T; Pivot X
    Breast; 2011 Aug; 20(4):329-33. PubMed ID: 21439823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.
    Pazdur R; Lassere Y; Diaz-Canton E; Ho DH
    Cancer Invest; 1998; 16(3):145-51. PubMed ID: 9541627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
    Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
    Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of UFT-oral vinorelbine in metastatic breast cancer.
    Ferrero JM; Largillier R; Michel C; Amiot V; Milano G; Hébert C; Mari V; Courdi A; Figl A; Follana P; Barrière J; Chamorey E
    Oncology; 2011; 81(2):73-8. PubMed ID: 21968516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer.
    Tedesco KL; Berlin J; Blanke CD; Teng M; Choy H; Roberts J; Beauchamp RD; Leach S; Wyman K; Tarpley J; Shyr Y; Caillouette C; Chakravarthy B
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1364-70. PubMed ID: 15817338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299.
    Hochster HS; Luo W; Popa EC; Lyman BT; Mulcahy M; Beatty PA; Benson AB
    J Clin Oncol; 2007 Dec; 25(34):5397-402. PubMed ID: 18048821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
    DeMario MD; Ratain MJ; Vogelzang NJ; Mani S; Vokes EE; Fleming GF; Melton K; Johnson S; Benner S; Lebwohl D
    Cancer Chemother Pharmacol; 1999; 43(5):385-8. PubMed ID: 10100593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.